ホーム › びまん性大細胞型B細胞リンパ腫 › フロリダ州
フロリダ州におけるびまん性大細胞型B細胞リンパ腫の臨床試験
フロリダ州内の拠点で、びまん性大細胞型B細胞リンパ腫に関する23件の研究が参加者を募集しています。
フロリダ州内の都市
公式研究テキスト（英語）
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0130), Boca Raton
- Baptist MD Anderson Cancer Center ( Site 0176), Jacksonville
- Mount Sinai Braman Comprehensive Cancer Center ( Site 0140), Miami Beach
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06890884A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton
- Clermont Oncology Center ( Site 0174), Clermont
- BRP-Hialeah Hospital ( Site 0182), Hialeah
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05139017A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Mayo Clinic Jacksonville, Jacksonville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06091865A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Clermont Oncology Center ( Site 0182), Clermont
- Bioresearch Partner ( Site 0157), Hialeah
- Orlando Health Cancer Institute ( Site 0169), Ocoee
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06717347A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- University of Miami - Sylvester Cancer Center, Miami
- Florida Cancer Specialists - Sarasota, Sarasota
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Johns Hopkins All Children's Hospital ( Site 1025), St. Petersburg
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
- Moffitt Cancer Center, Tampa
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT05757219Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- North Florida/ South Georgia VA Medical Center, Gainesville
- Mount Sinai Comprehensive Cancer Center, Miami
- Orlando Health Cancer Institute, Orlando
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06806033Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Miami Cancer Institute at Baptist Health, Inc., Miami
- Advent Health Cancer Institute, Orlando
- Orlando Health Cancer Institute, Orlando
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/31更新 · NCT06500273Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Florida, Jacksonville
- AdventHealth, Orlando
- Moffitt Cancer Center, Tampa
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Mayo Clinic, Jacksonville
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/30更新 · NCT07424833DALY II USA/ MB-CART2019.1 for DLBCL
- Baptist Health Miami Cancer Institute, Miami
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Moffitt Cancer Center, Tampa
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/09更新 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- ASCLEPES Research Centers, Weeki Wachee
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
- University of Miami Sylvester Cancer Center, Miami
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/05更新 · NCT05800366B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT06191887Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- UF Health Cancer Institute - Gainesville, Gainesville
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT05633615Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Mayo Clinic in Florida, Jacksonville
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/28更新 · NCT06834373Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Holy Cross Hospital, Fort Lauderdale
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05890352A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/02更新 · NCT05780034ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。